Literature DB >> 11525942

Inflammation in autoimmunity: receptors for IgG revisited.

H M Dijstelbloem1, J G van de Winkel, C G Kallenberg.   

Abstract

During the past decade, our knowledge of Fc receptor interactions in inflammation has increased dramatically owing to the availability of single and multiple Fc-receptor-deficient mice. The deletion of activating Fc gamma receptors protects against inflammation in models of immune-complex-mediated diseases, whereas the deletion of inhibitory Fc gamma receptors triggers increased susceptibility to immune-complex-induced inflammation. These new insights have a profound impact on our understanding of inflammation in autoimmune diseases, such as systemic lupus erythematosus (SLE). Comprehending the complex interactions between activating and inhibitory Fc gamma receptors might lead to new therapeutic approaches for human diseases, including SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525942     DOI: 10.1016/s1471-4906(01)02014-2

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  48 in total

1.  Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection.

Authors:  Jason M Zimmerer; Xin L Liu; Alecia Blaszczak; Christina L Avila; Thomas A Pham; Robert T Warren; Ginny L Bumgardner
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

Review 2.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 3.  Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: a negative times a negative makes a positive.

Authors:  Naoyuki Tsuchiya; Zen-Ichiro Honda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2006-09-01       Impact factor: 3.172

Review 4.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

5.  Making autoantibodies safe.

Authors:  Christopher N Scanlan; Dennis R Burton; Raymond A Dwek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-14       Impact factor: 11.205

6.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

7.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

8.  Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors.

Authors:  T R D J Radstake; R van der Voort; M ten Brummelhuis; M de Waal Malefijt; M Looman; C G Figdor; W B van den Berg; P Barrera; G J Adema
Journal:  Ann Rheum Dis       Date:  2004-08-26       Impact factor: 19.103

9.  Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of Cryptococcus neoformans through different receptors.

Authors:  Carolyn A Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 10.  The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy.

Authors:  J Griggs; K Zinkewich-Peotti
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.